gevokizumab open-label

DRUG2 trials

Sponsors

XOMA (US) LLC

Conditions

Pyoderma Gangrenosum

Phase 3

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

TerminatedNCT02315417

XOMA (US) LLCPyoderma Gangrenosum

Start: 2014-11-30End: 2016-03-31Updated: 2016-04-27

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

TerminatedNCT02326740

XOMA (US) LLCPyoderma Gangrenosum

Start: 2014-12-31End: 2016-03-31Updated: 2016-04-27